March 20, 2023
Astellas Pharma said on March 17 that Xtandi (enzalutamide), an androgen receptor inhibitor being developed with Pfizer, plus leuprolide hit the primary target in a global PIII study in certain patients with non-metastatic hormone-sensitive prostate cancer. The company plans to...read more